Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart chemotherapy outsmart resistant T-Cell cancers?

NCT ID NCT04315324

Disease control Sponsor: SWOG Cancer Research Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called OBI-3424 in people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has returned or not responded to treatment. The drug is designed to become active mainly inside cancer cells that produce a specific enzyme, potentially killing the cancer while sparing healthy cells. Researchers are looking for the safest and most effective dose, and whether the drug can shrink or eliminate the cancer. Participants will receive the drug through an IV and undergo regular blood tests, bone marrow samples, and imaging to monitor their response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OBI-3424, a chemotherapy prodrug that becomes active inside cancer cells with high levels of a specific enzyme (AKR1C3)
What this could lead to
If it works, this could offer a new treatment option for people with T-cell leukemia or lymphoma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial, so the drug may not work as hoped or may cause serious side effects. The results will need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 67 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have a diagnosis of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) based on World Health Organization (WHO) classification. Patients with relapsed/refractory T-cell lymphoblastic lymphoma are eligible if lymphoblasts are \>= 5% in the bone marrow or in the peripheral blood by morphology or flow cytometry * Patients must have evidence of acute leukemia in their peripheral blood or bone marrow. Patients must have \>= 5% lymphoblasts in the peripheral blood or bone marrow within 14 days prior to registration. Patients with only extramedullary disease are not eligible * Patients ≥ 18 years of age must be refractory to or have relapsed following a standard induction chemotherapy. Patients \< 18 years of age must have relapsed or must be refractory after 2 or more chemotherapy cycles (example: induction and consolidation) * A standard chemotherapy induction regimen is defined as any program of treatment that includes: * Vincristine and corticosteroids plus at least one more chemotherapy agent * Cytarabine and anthracycline, or * High dose cytarabine (defined as at least 1 gr/m\^2 per individual dose unless adjustments were required for renal/liver function) * Patients must have no evidence of central nervous system disease within 28 days prior to registration based on cerebrospinal fluid (CSF) studies. Patients with clinical signs or symptoms consistent with central nervous system (CNS) involvement must have a lumbar puncture which is negative for CNS involvement; the lumbar puncture must be completed within 28 days prior to registration. Patients with CNS1 or CNS2 are eligible; however patients with CNS3 are not eligible * Note that the patients may receive intrathecal chemotherapy with the initial lumbar puncture. This may count as the first dose of intrathecal therapy required as part of the study * Prior nelarabine therapy is not required. In addition, for patients ≥ 18 years of age who received nelarabine during initial induction or post-remission treatment are eligible only if the physician does not feel they would benefit from other, multi-agent chemotherapy * Patients must not have had chemotherapy or investigational agents within 14 days prior to registration except for corticosteroids, oral 6-mercaptopurine, oral methotrexate, vincristine, intrathecal chemotherapy, or hydroxyurea. For participants who have received radiation therapy, at least 7 days must have elapsed from the end of radiation prior to registration and participants must not currently be experiencing toxicities from radiation therapy * Patients must not have undergone allogeneic hematopoietic transplant within 90 days prior to registration * Patients must have no evidence of active \>= grade 2 acute graft versus host disease (GVHD) or moderate or severe limited chronic GVHD. Patients must have no history of extensive GVHD of any severity within 90 days prior to registration. Patients who are post-transplant must be off calcineurin inhibitors for at least 21 days to be eligible. Extensive GVHD is defined as 1) generalized skin involvement or 2) localized skin involvement and/or hepatic dysfunction plus liver histology or cirrhosis or involvement of eye or minor salivary organ or oral mucosa or any other target organ * Patients must be \>= 12 years of age * Patients ≥ 16 years of age must have a Zubrod Performance Status of 0-3. Patients \< 16 years of age must have a Lansky score of ≥ 50 * Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) within 14 days prior to registration * Patients ≥ 18 years of age must have creatinine clearance \> 30 mL/min within 14 days prior to registration according to the Cockcroft Gault equation * Patients 12-17 years of age must have adequate renal function within 14 days prior to registration defined as serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) according to age or a calculated estimated glomerular filtration rate (eGFR) (based on Schwartz formula) or radioisotope glomerular filtration rate (GFR) ≥ 50ml/min/1.73 m\^2 * Patients must have direct bilirubin =\< 1.5 x institutional upper limit of normal (ULN) within 14 days prior to registration * Patients must have alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN) or =\< 5.0 x ULN (if thought to be related to leukemic involvement) within 14 days prior to registration * Prothrombin time (PT)/partial thromboplastin time (PTT)/ fibrinogen (as clinically indicated for example but not limited to history of bleeding or active bleeding, concern for disseminated intravascular coagulation) (within 14 days prior to registration to obtain baseline measurements) * From metabolic panel (comprehensive or basic): sodium, potassium, chloride, carbon dioxide (CO2), and blood urea nitrogen (BUN) (within 14 days prior to registration to obtain baseline measurements) * Patients must be able to safely discontinue use of strong inhibitors/inducers of CYP3A4 or PgP-g-p and must be able to safely discontinue use of naproxen for 48 hours before and after each dose of OBI-3424 * Patients with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test within 6 months prior to registration. (HIV viral load testing is required only for patients with known HIV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients with evidence of chronic hepatitis B virus (HBV) infection may be eligible provided that they have an undetectable HBV viral load within 28 days prior to registration. Patients may be currently receiving HBV treatment. (HBV viral load testing is required only for patients with known HBV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients with known history of hepatitis C virus (HCV) infection may be eligible provided that they have an undetectable HCV viral load within in 28 days prior to registration. Patients may be currently receiving treatment. (HCV viral load testing is required only for patients with known HCV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients must not have a known history of prolonged QT interval by Fridericia (QTcF) (interval \> 450 msec for males; \> 470 msec for females). Patients that had transient prolongation of QTc secondary to medications or electrolyte abnormalities are not excluded if the QTc normalized and remain within acceptable QTcF range (interval \> 450 msec for males; \> 470 msec for females). Additionally, suspected medications should be no longer required or used, and electrolyte abnormalities must have normalized * Patients must not be pregnant or nursing due to the teratogenic potential of the drug used on this study. Females of reproductive potential must have a negative serum pregnancy test within 14 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method during and up to 6 months after treatment. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures * Patients must not have other active malignancies for which they have received treatments within 6 months prior to registration excluding localized malignancies that do not require systemic treatment * Patients must agree to have bone marrow and blood specimens submitted for MRD testing * Patients must be offered the opportunity to participate in specimen banking. With patient consent, residuals from specimens submitted will be retained and banked for future research * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with fedral, local, institutional and Central Institutional Review Board (CIRB) guidelines unless they are unable to provide consent based on age (\< 18 years) or based on impaired decision-making capabilities. For patients \< 18 years of age or with impaired decision making capabilities, parents or other legally authorized representatives must sign and give informed consent on behalf of study participants in accordance with applicable federal, local, institutional and CIRB regulations * As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * This trial will use a slot reservation system to enroll the Phase I portion of the study. Patients planning to enroll at this phase of the study must first have a slot reserved in advance of the registration. All site staff will use OPEN to create a slot reservation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent T acute lymphoblastic leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma refractory precursor T-lymphoblastic lymphoma/leukemia T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent T acute lymphoblastic leukemia Refractory T acute lymphoblastic leukemia Refractory T lymphoblastic lymphoma T lymphoblastic lymphoma

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    Minneapolis, Minnesota, 55407, United States

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware, 19803, United States

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation

    Las Vegas, Nevada, 89135, United States

  • Ann M Wierman MD LTD

    Las Vegas, Nevada, 89128, United States

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72202-3591, United States

  • Augusta University Medical Center

    Augusta, Georgia, 30912, United States

  • Beacon Kalamazoo

    Kalamazoo, Michigan, 49048, United States

  • Beacon Kalamazoo Cancer Center

    Kalamazoo, Michigan, 49009, United States

  • Bronson Battle Creek

    Battle Creek, Michigan, 49017, United States

  • Bronson Methodist Hospital

    Kalamazoo, Michigan, 49007, United States

  • Cambridge Medical Center

    Cambridge, Minnesota, 55008, United States

  • Cancer Center of Western Wisconsin

    New Richmond, Wisconsin, 54017, United States

  • Cancer and Blood Specialists-Henderson

    Henderson, Nevada, 89052, United States

  • Cancer and Hematology Centers of Western Michigan - Norton Shores

    Norton Shores, Michigan, 49444, United States

  • Carson Tahoe Regional Medical Center

    Carson City, Nevada, 89703, United States

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia, 30329, United States

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital and Medical Center of Omaha

    Omaha, Nebraska, 68114, United States

  • Children's Hospital of Orange County

    Orange, California, 92868, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania, 15224, United States

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia, 23507, United States

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri, 64108, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89148, United States

  • Comprehensive Cancer Centers of Nevada - Central Valley

    Las Vegas, Nevada, 89169, United States

  • Comprehensive Cancer Centers of Nevada - Henderson

    Henderson, Nevada, 89052, United States

  • Comprehensive Cancer Centers of Nevada - Northwest

    Las Vegas, Nevada, 89128, United States

  • Comprehensive Cancer Centers of Nevada - Town Center

    Las Vegas, Nevada, 89144, United States

  • Comprehensive Cancer Centers of Nevada-Horizon Ridge

    Henderson, Nevada, 89052, United States

  • Comprehensive Cancer Centers of Nevada-Southeast Henderson

    Henderson, Nevada, 89074, United States

  • Comprehensive Cancer Centers of Nevada-Summerlin

    Las Vegas, Nevada, 89144, United States

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan, 49503, United States

  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

    Grand Rapids, Michigan, 49503, United States

  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Lakeland Hospitals - Niles Hospital

    Niles, Michigan, 49120, United States

  • Corewell Health Lakeland Hospitals - Saint Joseph Hospital

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Reed City Hospital

    Reed City, Michigan, 49677, United States

  • Dell Children's Medical Center of Central Texas

    Austin, Texas, 78723, United States

  • Desert West Surgery

    Las Vegas, Nevada, 89102, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • El Paso Children's Hospital

    El Paso, Texas, 79905, United States

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Fairview Clinics and Surgery Center Maple Grove

    Maple Grove, Minnesota, 55369, United States

  • Fairview Lakes Medical Center

    Wyoming, Minnesota, 55092, United States

  • Fairview Northland Medical Center

    Princeton, Minnesota, 55371, United States

  • Fairview Ridges Hospital

    Burnsville, Minnesota, 55337, United States

  • Fairview Southdale Hospital

    Edina, Minnesota, 55435, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • GenesisCare USA - Fort Apache

    Las Vegas, Nevada, 89148, United States

  • GenesisCare USA - Henderson

    Henderson, Nevada, 89074, United States

  • GenesisCare USA - Las Vegas

    Las Vegas, Nevada, 89109, United States

  • GenesisCare USA - Vegas Tenaya

    Las Vegas, Nevada, 89128, United States

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida, 33908, United States

  • Gundersen Lutheran Medical Center

    La Crosse, Wisconsin, 54601, United States

  • Health Partners Inc

    Minneapolis, Minnesota, 55454, United States

  • HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

    Las Vegas, Nevada, 89149, United States

  • HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

    Las Vegas, Nevada, 89109, United States

  • HealthCare Partners Medical Group Oncology/Hematology-San Martin

    Las Vegas, Nevada, 89113, United States

  • HealthCare Partners Medical Group Oncology/Hematology-Tenaya

    Las Vegas, Nevada, 89128, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • Hope Cancer Care of Nevada

    Las Vegas, Nevada, 89103, United States

  • Hope Cancer Care of Nevada-Pahrump

    Pahrump, Nevada, 89048, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida, 33701, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Kingman Regional Medical Center

    Kingman, Arizona, 86401, United States

  • LSU Health Baton Rouge-North Clinic

    Baton Rouge, Louisiana, 70805, United States

  • Lakeview Hospital

    Stillwater, Minnesota, 55082, United States

  • Las Vegas Cancer Center-Henderson

    Henderson, Nevada, 89052, United States

  • Las Vegas Cancer Center-Medical Center

    Las Vegas, Nevada, 89148-2405, United States

  • Las Vegas Prostate Cancer Center

    Las Vegas, Nevada, 89113, United States

  • Las Vegas Urology - Cathedral Rock

    Las Vegas, Nevada, 89128, United States

  • Las Vegas Urology - Green Valley

    Henderson, Nevada, 89074, United States

  • Las Vegas Urology - Pebble

    Henderson, Nevada, 89074, United States

  • Las Vegas Urology - Pecos

    Las Vegas, Nevada, 89074, United States

  • Las Vegas Urology - Smoke Ranch

    Las Vegas, Nevada, 89128, United States

  • Las Vegas Urology - Sunset

    Las Vegas, Nevada, 89113, United States

  • Loma Linda University Medical Center

    Loma Linda, California, 92354, United States

  • Loyola Center for Health at Burr Ridge

    Burr Ridge, Illinois, 60527, United States

  • Loyola Medicine Homer Glen

    Homer Glen, Illinois, 60491, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois, 60611, United States

  • Marjorie Weinberg Cancer Center at Loyola-Gottlieb

    Melrose Park, Illinois, 60160, United States

  • Mary Greeley Medical Center

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Ames

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa, 50501, United States

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida, 33021, United States

  • Mercy Hospital

    Coon Rapids, Minnesota, 55433, United States

  • Methodist Children's Hospital of South Texas

    San Antonio, Texas, 78229, United States

  • Minnesota Oncology - Burnsville

    Burnsville, Minnesota, 55337, United States

  • Minnesota Oncology Hematology PA-Maplewood

    Maplewood, Minnesota, 55109, United States

  • Minnesota Oncology Hematology PA-Woodbury

    Woodbury, Minnesota, 55125, United States

  • Monticello Cancer Center

    Monticello, Minnesota, 55362, United States

  • Munson Medical Center

    Traverse City, Michigan, 49684, United States

  • New Ulm Medical Center

    New Ulm, Minnesota, 56073, United States

  • North Memorial Medical Health Center

    Robbinsdale, Minnesota, 55422, United States

  • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

    Yakima, Washington, 98902, United States

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois, 60045, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Norton Children's Hospital

    Louisville, Kentucky, 40202, United States

  • OptumCare Cancer Care at Charleston

    Las Vegas, Nevada, 89102, United States

  • OptumCare Cancer Care at Fort Apache

    Las Vegas, Nevada, 89148, United States

  • OptumCare Cancer Care at MountainView

    Las Vegas, Nevada, 89128, United States

  • OptumCare Cancer Care at Seven Hills

    Henderson, Nevada, 89052, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana, 70808, United States

  • Overlake Medical Center

    Bellevue, Washington, 98004, United States

  • PCR Oncology

    Arroyo Grande, California, 93420, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Prisma Health Richland Hospital

    Columbia, South Carolina, 29203, United States

  • Radiation Oncology Associates

    Reno, Nevada, 89509, United States

  • Radiation Oncology Centers of Nevada Central

    Las Vegas, Nevada, 89106, United States

  • Radiation Oncology Centers of Nevada Southeast

    Las Vegas, Nevada, 89119, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Renown Regional Medical Center

    Reno, Nevada, 89502, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • Rice Memorial Hospital

    Willmar, Minnesota, 56201, United States

  • Ridgeview Medical Center

    Waconia, Minnesota, 55387, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Saint Francis Regional Medical Center

    Shakopee, Minnesota, 55379, United States

  • Saint John's Hospital - Healtheast

    Maplewood, Minnesota, 55109, United States

  • Saint Mary's Regional Medical Center

    Reno, Nevada, 89503, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Summerlin Hospital Medical Center

    Las Vegas, Nevada, 89144, United States

  • Sunrise Hospital and Medical Center

    Las Vegas, Nevada, 89109, United States

  • The Children's Hospital at TriStar Centennial

    Nashville, Tennessee, 37203, United States

  • Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan, 49503, United States

  • Trinity Health Muskegon Hospital

    Muskegon, Michigan, 49444, United States

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois, 60451, United States

  • United Hospital

    Saint Paul, Minnesota, 55102, United States

  • Unity Hospital

    Fridley, Minnesota, 55432, United States

  • University Cancer Center

    Las Vegas, Nevada, 89169, United States

  • University Medical Center of Southern Nevada

    Las Vegas, Nevada, 89102, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois, 60462, United States

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio, 45069, United States

  • University of Illinois

    Chicago, Illinois, 60612, United States

  • University of Michigan Health - West

    Wyoming, Michigan, 49519, United States

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, 87106, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • University of Washington Medical Center - Montlake

    Seattle, Washington, 98195, United States

  • Urology Specialists of Nevada - Central

    Las Vegas, Nevada, 89106, United States

  • Urology Specialists of Nevada - Green Valley

    Henderson, Nevada, 89074, United States

  • Urology Specialists of Nevada - Northwest

    Las Vegas, Nevada, 89128, United States

  • Urology Specialists of Nevada - Southwest

    Las Vegas, Nevada, 89113, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

  • Valley Medical Center

    Renton, Washington, 98055, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

  • West Michigan Cancer Center

    Kalamazoo, Michigan, 49007, United States

  • West Virginia University Healthcare

    Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.